Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1984 2
1986 1
1989 1
1990 3
1991 1
1992 3
1993 3
1997 2
1998 2
1999 1
2000 2
2001 3
2002 2
2003 1
2004 4
2005 7
2006 10
2007 4
2008 2
2009 1
2010 3
2011 3
2012 5
2013 4
2014 11
2015 16
2016 7
2017 8
2018 10
2019 5
2020 5
2021 6
2022 8
2023 16

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. Coskun T, et al. Among authors: thomas mk. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9. doi: 10.1016/j.cmet.2022.07.013. Epub 2022 Aug 18. Cell Metab. 2022. PMID: 35985340 Free article.
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z. Heise T, et al. Among authors: thomas mk. Lancet Diabetes Endocrinol. 2022 Jun;10(6):418-429. doi: 10.1016/S2213-8587(22)00085-7. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468322 Clinical Trial.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. Urva S, et al. Among authors: thomas mk. Lancet. 2022 Nov 26;400(10366):1869-1881. doi: 10.1016/S0140-6736(22)02033-5. Epub 2022 Oct 27. Lancet. 2022. PMID: 36354040 Clinical Trial.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Rosenstock J, et al. Among authors: thomas mk. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385280 Clinical Trial.
The need for unrealistic experiments in global change biology.
Collins S, Whittaker H, Thomas MK. Collins S, et al. Among authors: thomas mk. Curr Opin Microbiol. 2022 Aug;68:102151. doi: 10.1016/j.mib.2022.102151. Epub 2022 May 4. Curr Opin Microbiol. 2022. PMID: 35525129 Free article. Review.
Toward an integration of evolutionary biology and ecosystem science.
Matthews B, Narwani A, Hausch S, Nonaka E, Peter H, Yamamichi M, Sullam KE, Bird KC, Thomas MK, Hanley TC, Turner CB. Matthews B, et al. Among authors: thomas mk. Ecol Lett. 2011 Jul;14(7):690-701. doi: 10.1111/j.1461-0248.2011.01627.x. Epub 2011 May 9. Ecol Lett. 2011. PMID: 21554512 Review.
148 results